Clinical implication of maximal voluntary ventilation in myotonic muscular dystrophy

Mi Ri Suh, MD*a,b,c,d, Dong Hyun Kim, MD, PhD*e, Jiho Jung, MD*f, Bitnarae Kim, PT, BScf,g, Jang Woo Lee, MDc,h, Won Ah Choi, MD, PhDc,i,j, Seong-Woong Kang, MD, PhDc,i,*

Abstract
Patients with myotonic muscular dystrophy type 1 (DM1) tend to exhibit earlier respiratory insufficiency than patients with other neuromuscular diseases at similar or higher forced vital capacity (FVC). This study aimed to analyze several pulmonary function parameters to determine which factor contributes the most to early hypercapnia in patients with DM1.

We analyzed ventilation status monitoring, pulmonary function tests (including FVC, maximal voluntary ventilation [MVV], and maximal inspiratory and expiratory pressure), and polysomnography in subjects with DM1 who were admitted to a single university hospital. The correlation of each parameter with hypercapnia was determined. Subgroup analysis was also performed by dividing the study subjects into 2 subgroups according to usage of mechanical ventilation.

Final analysis included 50 patients with a mean age of 42.9 years (standard deviation = 11.1), 46.0% of whom were male. The hypercapnia was negatively correlated with MVV, FVC, forced expiratory volume in 1 second (FEV1), and their ratios to predicted values in subjects with myotonic muscular dystrophy type 1. At the same partial pressure of carbon dioxide, the ratio to the predicted value was lowest for MVV, then FEV1, followed by FVC. Moreover, the P values for differences in MVV and its ratio to the predicted value between ventilator users and nonusers were the lowest.

When screening ventilation failure in patients with DM1, MVV should be considered alongside other routinely measured parameters.

Abbreviations: CTG = cytosine–thymine–guanine, DM1 = myotonic muscular dystrophy type 1, DMPK = dystrophia myotonica protein kinase, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, MEP = maximal expiratory pressure, MIP = maximal inspiratory pressure, MMD = myotonic muscular dystrophy, MVV = maximal voluntary ventilation, pCO2 = partial pressure of carbon dioxide.

Keywords: forced vital capacity, hypercapnia, maximal voluntary ventilation, myotonic muscular dystrophy, neuromuscular disease, ventilation failure

1. Introduction
Myotonic muscular dystrophy type 1 (DM1), caused by an abnormal cytosine–thymine–guanine (CTG) repeat expansion in the region of the dystrophia myotonica protein kinase (DMPK) gene,1–4 is one of the most common neuromuscular diseases. The expanded repeat is transcribed in RNA and forms discrete inclusions in the nucleus, leading to muscle fiber hyperexcitability and impaired transmembrane conductance of either chloride or sodium ions.5,6 Patients are characterized by “myotonia,” a term referring to delayed relaxation of muscle fibers. Thus, unlike patients with other types of neuromuscular diseases who exhibit only progressive loss of muscle fibers, patients with DM1 exhibit difficulty in contraction–relaxation coordination before exhibiting actual muscle weakness.7 Symptomatic patients demonstrate difficulty in relaxing their grip during repeated grasping and releasing movements. Cardiac muscles predominantly exhibit...
rhythmic problems such as conduction abnormalities, and cardiomyopathies are usually secondary to arrhythmia and ventilatory failure.[4–7] Most likely, the diaphragm and intercostal muscles, which enable rhythmic breathing by contraction and passive relaxation, can also be affected by myotonia.[8,9]

Most neuromuscular disorders, including DM1, with progressive respiratory muscle weakness result in an increase in partial pressure of carbon dioxide (pCO₂).[11,12] and hypercapnia demonstrates a correlation with pulmonary function.[13] For example, decline in total lung capacity is strongly correlated with hypoxemia and hypercapnia in patients with myotonic muscular dystrophy (MMD).[14] However, in our experience, patients with DM1 tend to exhibit earlier respiratory insufficiency than patients with other neuromuscular diseases at similar or higher pulmonary function, including forced vital capacity (FVC).[15]

Aside from respiratory muscle weakness, there are also other mechanisms that explain ventilation failure in DM1, including alterations in respiratory mechanics and abnormal central respiratory control.[16–18]

Meanwhile, maximal voluntary ventilation (MVV) is one of the pulmonary function parameters used to determine respiratory muscle endurance. The standard method of measuring MVV is to let the patient breathe as fast and hard as possible for 12 seconds, then multiply the total flow volume by 5 to yield the total volume of ventilation per minute (expressed as L/min).[17] Unlike most of other parameters that measure the pulmonary function for brief seconds, MVV enables measurement of longer flows. Reductions in MVV were known to be associated with respiratory phase slowing in the previous report.[17] Theoretically, it reflects both inspiratory and expiratory phase dysfunction and airway resistance, for MVV measures maximal volume of air inspired and expired for brief seconds. Unlike most other parameters that measure the pulmonary function for brief seconds, MVV enables measurement of longer flows. Reductions in MVV were known to be associated with respiratory phase slowing in the previous report.[17] Theoretically, it reflects both inspiratory and expiratory phase dysfunction and airway resistance, for MVV measures maximal volume of air inspired and expired for brief seconds.[17]

Myotonia of the diaphragm—typical in patients with DM1—might not easily be detected in shorter phase examinations such as FVC or forced expiratory volume in 1 second (FEV₁). However, it can be revealed in examinations conducted for longer phases, such as MVV.

We hypothesized that MVV decreases before other parameters, such as FVC, in patients with DM1, and that MVV would decline more abruptly in correlation with the progression of respiratory dysfunction in these patients. Accordingly, this study aimed to analyze several pulmonary function parameters to determine which factor contributes the most to early hypercapnia in patients with DM1.

2. Materials and methods

2.1. Participants

This is an observation study enrolling subjects with DM1 who were admitted to a single university hospital for routine annual check-up between March 2015 and March 2018. Individuals who were not able to undergo the pulmonary function tests (e.g., those with intellectual disabilities), and those with acute pulmonary disease conditions (e.g., pneumonia, pneumothorax, and so on) which may have affected the test results, were excluded. This study was approved by the institutional review board of the authors’ hospital (3-2016-0182).

2.2. Study design

We retrospectively collected the data of pulmonary function testing, including FVC, FEV₁, and MVV. Data of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were also collected.

FVC which is the complete expiratory volume from a position of full inspiration[19] and FEV₁ which reflects elastic recoil and airway resistance[20] (both measured simultaneously) were tested using spirometry (Pony FX, COSMED, Rome, Italy) at least 3 times, and the best results were recorded. Normal predicted values for FVC were determined,[19,21] and the ratio of actual measurements and the predicted value (FVCpred%) in each subject were calculated. The ratio of FEV₁ to FVC (FEV₁/FVC) was also calculated. The MVV, which is understood as maximum ventilatory capacity[22] reflecting both inspiratory and expiratory phase dysfunction and airway resistance,[18] was tested also using Pony FX for a 12-second period, and the result was calculated to obtain a L/min value. At least 2 MVV data points were obtained with at least 1-minute time interval, and the highest value was recorded. Predicted value for MVV (MVVpred%) was also determined based on previous studies[17,23]; and the ratio of actual measurements and the predicted value of each subject were calculated. Both MIP and MEP which measure the strength of each inspiratory and expiratory muscles[24] were performed using respiratory pressure manometer (MicroRPM, CareFusion, Hoechberg, Germany) until 2 maximal values were reproducible, and the greatest pressure value obtained with variation <10% among the 3 highest values was chosen. The measured value and the percentage of the expected normal value (MIPpred% and MEPpred%) were considered.[21] Each test maneuver was performed together by a doctor and a trained physical therapist, and brief demonstration of each maneuver was conducted before initiating the test.

The pCO₂ was measured overnight in a noninvasive and continuous manner using a transcutaneous oximetry/capnometry device (SenTec AG; Thierwil, Milwaukee, WI),[25] without a mechanical ventilator, and the maximal value of measured transcutaneous CO₂ was considered. We considered the pCO₂ value because the ventilatory dysfunction in this group is generally due to alveolar hypoventilation,[11,12] which can be predicted by isolated nocturnal hypercapnia.[24] Apnea–hypopnea index was also calculated from polysomnography performed on the same night (SleepTrek3; Grass Technologies, West Warwick, RI).

We first analyzed the pulmonary function parameters (i.e., FVC, FVCpred%, FEV₁, FEV₁pred%, FEV₁/FVC, MVV, MVVpred%, MIP, MIPpred%, MEP, and MEPpred%) and demographic data (i.e., age, height, weight, body mass index, duration from initiation of mechanical ventilation, and number of CTG repeats), and their correlation with pCO₂. Then we performed subgroup analysis by dividing the subjects into 2 subgroups according to usage of mechanical ventilation. We compared the mean values of each pulmonary function parameters among the subgroups.

2.3. Statistical analysis

The aim of this study was to determine the correlation between pCO₂ and the pulmonary function parameters. As this was the first study to determine this correlation, we set to get significant result (P < .05) with sufficient power (80%) to detect at least correlation of 0.4. Therefore, the minimum required sample size for this study was 46.

Bivariate analysis was performed for each pulmonary function parameter, including MVV, FVC, FEV₁, MIP, MEP, and ratios of
their measure values to predicted values. Trend lines were drawn for the measured value/predicted values of FVC, FEV1, and MVV on a scatter plot. The independent t test was used to compare the mean values of each parameter in the subgroup analysis. Missing data were not included in the analysis. The software SPSS version 24 (IBM Corp., Armonk, NY) was used. Values of P < .05 were considered statistically significant.

3. Results

3.1. Basic demographic information

Among the 87 eligible subjects, pulmonary function evaluation was performed in 50 subjects (mean age: 42.9 ± 11.1 years) with DM1. Test was not available in 13 subjects due to intellectual disabilities, and in 24 subjects due to acute medical conditions. Diagnostic confirmation was made by electrodiagnostic study and genetic study, showing abnormal GTC repeat expansion on DMPK gene. Sex was evenly distributed in the subject group with DM1, 46.0% of whom were male. Percussion myotonia was detected in all except 2 subjects, whereas grip myotonia was noticed in 26 subjects. The anthropometric data of the subjects are summarized in Table 1. Thirty-six out of the 50 subjects with DM1 were under mechanical ventilation. Only 14 subjects had polysomnography data.

3.2. Comparing ventilator users versus nonusers with DM1

We divided the subjects into 2 groups according to usage of mechanical ventilation. Thirty-six subjects were under mechanical ventilation with 35.9 months of mean duration since initiation and 14 subjects were nonusers. The initiation of mechanical ventilation in this group was decided under previously described criteria[27–29] and procedures.[29] Although they showed difference in age, the difference was not statistically significant. Mean pCO2 of ventilator users and nonusers was 45.0 and 37.0 mm Hg, respectively (P = .001). The parameters FVC, FVCpred%, FEV1, FEV1pred%, MVV, and MVVpred% all showed significant differences between the 2 subgroups, but the P values for the differences in MVV and MVVpred% were lower than those for other parameters (Table 1).

3.3. Correlation between pulmonary function parameters and trends of decline

Most of the pulmonary function test parameters demonstrated significant correlation with one another in subjects with DM1 in the bivariate analysis. Table 2 shows bivariate correlation between hypercapnia and the pulmonary function parameters. It shows significant correlation of FVC, FVCpred%, FEV1, FEV1pred%, MVV, and MVVpred% with hypercapnia. Furthermore, hypercapnia showed significant correlation with duration from initiation of mechanical ventilation for subjects under mechanical ventilation (r = −.390, P = .02). However, it did not show significant correlation with age (r = −.031, P = .83), height (r = −.009, P = .95), weight (r = 0.099, P = .49), body mass index (r = 0.115, P = .43), CTG repeats (r = −.021, P = .90), nor apnea–hypopnea index (r = 0.475, P = .09).

Figure 1 shows the trend lines drawn for measured/predicted value (%) of FVC, FEV1, and MVV on a scatter plot. The trend lines for DM1 ran parallel. At the same given pCO2, the measured/predicted value of MVV was the lowest while that of FVC was the highest.

Table 1

| Parameter                  | Total (n = 50) | Ventilator users (n = 36) | Nonusers (n = 14) | P     |
|----------------------------|----------------|--------------------------|------------------|-------|
| Age, y                     | 42.9 ± 11.1    | 42.9 ± 11.1              | 22.2 ± 5.3       | .06   |
| Height, cm                 | 162.9 ± 7.8    | 162.9 ± 7.8              | 164.4 ± 6.9      | .35   |
| Weight, kg                 | 59.9 ± 15.2    | 59.4 ± 16.5              | 61.2 ± 11.7      | .66   |
| BMI                        | 22.6 ± 5.6     | 22.5 ± 6.1               | 22.7 ± 4.2       | .03   |
| CTG repeat*                | 530.1 ± 338.5  | 540.2 ± 401.3            | 533.3 ± 134.3    | .94   |
| AH†                        | 32.6 ± 20.8    | 32.6 ± 20.8              | NA               |       |
| pCO2, mm Hg                | 42.7 ± 7.0     | 45.0 ± 6.8               | 37.3 ± 3.2       | .<.001|
| FVC, L                     | 2.9 ± 0.9      | 1.8 ± 1.0                | 2.4 ± 0.7        | .04†  |
| FVCpred, %                 | 54.2 ± 19.4    | 50.4 ± 19.5              | 63.8 ± 16.2      | .02   |
| FEV1, L                    | 1.5 ± 0.6      | 1.4 ± 0.7                | 1.8 ± 0.4        | .02†  |
| FEV1/FVC, %                | 54.2 ± 19.4    | 46.7 ± 18.5              | 57.6 ± 14.2      | .03†  |
| FEV1/FVC pred, %           | 77.8 ± 16.6    | 77.6 ± 17.4              | 77.7 ± 14.8      | .99   |
| MWV, L/mm                  | 46.5 ± 22.5    | 42.0 ± 24.0              | 58.1 ± 12.2      | .003† |
| MVVpred, %                 | 44.9 ± 17.8    | 39.9 ± 18.1              | 54.5 ± 12.2      | .002† |
| MP, cmH2O                  | 41.2 ± 16.1    | 40.6 ± 17.7              | 42.9 ± 11.3      | .58   |
| MVVpred, %                 | 50.4 ± 18.6    | 49.4 ± 19.2              | 53.0 ± 17.4      | .54   |
| MEP, cmH2O                 | 44.5 ± 15.4    | 43.9 ± 17.5              | 45.9 ± 8.2       | .68   |
| MVVpred, %                 | 40.2 ± 14.6    | 39.5 ± 15.2              | 42.6 ± 13.5      | .45   |

Data presented as mean ± standard deviation.

AH† = apnea–hypopnea index; BMI = body mass index; CTG = cytosine–thymine–guanine; DM1 = myotonic muscular dystrophy type 1; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; MEP = maximal expiratory pressure; MVV = maximal voluntary ventilation; N/A = not applicable; pCO2 = partial pressure of carbon dioxide; Pred = predicted.

*Mean CTG repeat was calculated among 32 out of 36 ventilator user and 9 out of 14 nonusers in subjects with DM1.

† Polysomnography was performed among 14 subjects only in the ventilator user group.

‡P < .05 and †P < .01 comparing the values among ventilator users and nonusers.

Table 2

| Parameter                  | DM1 (n = 50) |
|----------------------------|--------------|
| FVC                        | −0.298 (0.04)|
| FVCpred                    | −0.362 (0.01)|
| FEV1                       | −0.301 (0.03)|
| FEV1pred                   | −0.345 (0.01)|
| FVC/FVC                    | 0.003 (0.98)|
| MVV                        | −0.291 (0.04)|
| MVVpred                    | −0.353 (0.01)|
| MEP                        | −0.140 (0.33)|
| MEPpred                    | −0.185 (0.20)|
| MEP                        | −0.160 (0.28)|
| MEPpred                    | −0.236 (0.10)|

Data are shown as Pearson coefficient (P value).

*P < .05.
**P < .01.

DM1 = myotonic muscular dystrophy type 1; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; MEP = maximal expiratory pressure; MVV = maximal inspiratory pressure; MVV = maximum voluntary ventilation.
diaphragm in DM1 would affect the physiologic breathing rhythm and lead to the progression of ventilation failure, even with adequate vital capacity. We hypothesized that MVV decreases before other parameters, such as FVC, in subjects with DM1, and that MVV would decline more abruptly in correlation with progression of respiratory dysfunction in subjects with DM1.

In this study, we performed correlation analysis of different pulmonary function parameters with hypercapnia in subjects with DM1. FVC, FEV1, and MVV demonstrated a significant negative correlation with hypercapnia, whereas MIP and MEP did not. Although the declining pattern of MVV was not significantly different compared with FVC or FEV1 as we hypothesized, MVV\textsubscript{Pred}% decreased first among all the parameters. Moreover, the P value for the difference in MVV\textsubscript{Pred}% between ventilator users and nonusers was the lowest. Although performed in part of the study population, apnea index did not show significant correlation with pCO2.

Chronic hypoverilation in MMD has been explained in various prior studies. A central cause of hypoventilation is dominant among the theories posited by these studies. Carroll et al\cite{30} suggested the possibility of a central factor underlying respiratory dysfunction in MMD by showing decreasing respiratory response with increasing CO2 concentration. Although Begin et al\cite{31} opposed this idea by demonstrating that decreased respiratory response may not be due to a central factor, Serisier et al\cite{33} insisted that dysfunction of medullary respiratory control is related to decreased respiratory response in MMD because this cannot be explained purely by respiratory muscle weakness. Poussel et al\cite{14} insisted that alveolar hypoventilation in DM1 is independent of respiratory weakness, and provide evidences to support a central cause of CO2 insensitivity. Furthermore, studies have reported neuronal loss in the medullary respiratory center in MMD.\cite{34-36} Other evidences also support the association between respiratory muscle weakness and respiratory dysfunction. Misuri et al\cite{16} reported that elastic load and respiratory muscle weakness are responsible for a rapid and shallow breathing pattern, leading to chronic CO2 retention in patients with neuromuscular diseases, which is similar to the suggestion of Begin et al.\cite{31,32}

Nevertheless, apnea index and pulmonary function parameters representing respiratory muscle power, such as MIP and MEP, did not show better correlation with hypercapnia than FVC, FEV1, or MVV in subjects with DM1. The earliest reduction was observed in MVV\textsubscript{Pred}% and the P values for the differences in MVV and MVV\textsubscript{Pred}% were the least between the subjects with DM1 who were under mechanical ventilation and those who were not. We focused on dysfunction of elastic recoil or myotonic features of the respiratory muscles in this patient group to obtain an additional explanation of the cause of chronic hypoventilation.

Many studies have been conducted on myotonic movements in the respiratory muscles of patients with MMD. Fluoroscopic findings have revealed jerky movements of diaphragm and delayed relaxation patterns into normal position after contraction.\cite{37} Electromyographic findings have revealed the myotonic movements in the respiratory muscles of these patients.\cite{10,38} Recently, low maximum relaxation rate compared with healthy
subjects has also been shown to indicate delayed relaxation of the respiratory muscles in DM1.\[39\] However, previous studies have not investigated the relationship between the abnormal movement pattern of the respiratory muscle and respiratory dysfunction.

It is known that MVV is dependent on both inspiratory and expiratory breathing effort; inspiratory air flow is dependent on muscle power, whereas expiratory air flow relies mainly on lung recoil.\[40\] In normal subjects, lung recoil is known to be the major determinant of expiratory air flow in performing MVV. The same would apply to patients with DM1, given that they also perform MVV in the midrange of vital capacity. In this sense, MVV reflects the efficiency of lung recoil. The breathing pattern in MMD was described in a study by Bogaard et al.,[41] who described a wide range of irregularity during the entire breathing period. Accordingly, pulmonary parameters that are based on instantaneous values, such as MIP, MEP, and even FVC, may not accurately reflect the variant pattern of respiration in patients with DM1. Thus, MVV may be more informative in reflecting the respiratory status of these patients.

The limitations of this study include lack of sensitivity/specificity evaluation of MVV in relation to actual electromyo-graphic patterns of the respiratory muscles in subjects with DM1. The relatively small number of subjects who underwent polysomnography is another limitation. However, this study focuses on the declining trend of MVV in DM1 compared with other pulmonary function parameters, not its exact significance. Furthermore, this study does not aim to oppose the role of central dysfunction in chronic hypventilation in this disease group, rather suggesting additional consideration. Further studies including sensitivity/specificity evaluation of MVV and its comparison with other measures, such as maximum relaxation rate\[39\] and larger sample sizes with more apnea index data, will be necessary to support our results.

This study demonstrates a correlation between MVV, along with FVC and FEV₁, and the progression of respiratory dysfunction in patients with DM1. Not being a well-studied pulmonary function parameter, MVV is excluded from routine pulmonary function tests in most laboratories. However, lower MVV may be one of the most relevant parameters and one of the early signs of CO₂ retention in patients with DM1. Thus, while screening ventilation failure in patients with DM1, MVV should be carefully considered alongside other routine measures.

**Acknowledgments**

We express our gratitude toward their support.

**Author contributions**

Conceptualization: Dong Hyun Kim, Jang Woo Lee, Won Ah Choi, Seong-Woong Kang.

Data curation: Mi Ri Suh, Dong Hyun Kim, Jiho Jung, Bitnarae Kim, Jang Woo Lee.

Formal analysis: Mi Ri Suh, Jiho Jung, Bitnarae Kim, Jang Woo Lee.

Funding acquisition: Won Ah Choi, Seong-Woong Kang.

Investigation: Mi Ri Suh, Dong Hyun Kim, Jiho Jung, Bitnarae Kim, Jang Woo Lee, Won Ah Choi.

Methodology: Jang Woo Lee, Seong-Woong Kang.

Project administration: Won Ah Choi.

**Supervision:** Dong Hyun Kim, Won Ah Choi, Seong-Woong Kang.

**Writing – original draft:** Mi Ri Suh.

**Writing – review and editing:** Mi Ri Suh, Dong Hyun Kim.

Seong-Woong Kang orcid: 0000-0002-7279-3893.

**References**

[1] Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012;11:891–903.

[2] Hahn C, Salajegheh MK. Myotonic disorders: a review article. Iran J Neurol 2016;15:46–33.

[3] Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 2015;1852:594–606.

[4] LoRusso S, Weiner B, Arnold WD. Myotonic Dystrophies: Targeting Therapies for Multisystem Disease. Neurotherapeutics 2018;15:872–84.

[5] Markodi A. Myotonic disorders. Neurol India 2008;56:299–304.

[6] Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 2007;1772:195–204.

[7] Machuca-Tzilh L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005;32:1–8.

[8] Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005;15:5–16.

[9] Gagnon C, Noreau L, Morley RT, et al. Towards an integrative approach to the management of myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry 2007;78:800–6.

[10] Rimmer KP, Golar SD, Lee MA, et al. Myotonia of the respiratory muscles in myotonic dystrophy. Am Rev Respir Dis 1993;148(4 Pt. 1):1018–22.

[11] Panitch HB. The pathophysiology of respiratory impairment in pediatric neuromuscular diseases. Pediatrics 2009;123(Suppl. 4):S215–8.

[12] Vazquez-Sandoval A, Huang EJ, Jones SF. Hypoventilation in neuromuscular disease. Semin Respir Crit Care Med 2009;30:348–58.

[13] Toussaint M, Steens M, Soudou P. Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy. Chest 2007;131:368–75.

[14] Pousset M, Thié, Kaminsky P, et al. Lack of correlation between the ventilatory response to CO₂ and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level. Neuromuscul Disord 2015;25:403–8.

[15] Cho HF, Lee JW, Kang SW, et al. Comparison of pulmonary functions at onset of ventilatory insufficiency in patients with amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and myotonic muscular dystrophy. Ann Rehabil Med 2016;40:74–80.

[16] Misuri G, Lamini B, Gigliotti F, et al. Mechanism of CO₂ retention in patients with neuromuscular disease. Chest 2000;117:447–53.

[17] Kor AC, Ong KC, Earnest A, et al. Prediction of the maximal voluntary ventilation in healthy adult Chinese subjects. Respiratory 2004;9:76–80.

[18] Suh Y, Lee C. Genome-wide association study for genetic variants related with maximal voluntary ventilation reveals two novel genomic signals associated with lung function. Medicine 2017;96:e8530.

[19] Booker R. Interpretation and evaluation of pulmonary function tests. Nurs Stand 2009;23:46–56.

[20] Ruppel GL, Enright PL. Pulmonary function testing. Respir Care 2012;57:165–75.

[21] Won YH, Choi WA, Kim DH, et al. Postural vital capacity difference with aging in Duchenne muscular dystrophy. Muscle Nerve 2015;52:722–7.

[22] Cid-Juarez S, Perez-Padilla R, Torre-Bouscoudry L, et al. Maximum voluntary ventilation in a population residing at 2,240 meters above sea level. Respir Care 2017;62:1588–93.

[23] Campbell SC. A comparison of the maximum voluntary ventilation with the forced expiratory volume in one second: an assessment of subject cooperation. J Occup Med 1982;24:533–8.

[24] Fregonezi G, Azevedo IG, Resquet VR, et al. Muscle impairment in neuromuscular disease using an expiratory/inspiratory pressure ratio. Respir Care 2015;60:533–9.

[25] Won YH, Choi WA, Lee JW, et al. Sleep Transcutaneous vs. End-Tidal CO₂ Monitoring for Patients with Neuromuscular Disease. Am J Phys Med Rehabil 2016;95:91–5.
[26] Trucco F, Pedemonte M, Fiorillo C, et al. Detection of early nocturnal hypoventilation in neuromuscular disorders. J Int Med Res 2018;46:1153–61.

[27] Birnkrant DJ, Bushby KM, Amin RS, et al. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010;45:739–48.

[28] Hess DR. The growing role of noninvasive ventilation in patients requiring prolonged mechanical ventilation. Respir Care 2012;57:900–18.

[29] Suh MR, Choi WA, Kim DH, et al. Five-year follow-up and outcomes of noninvasive ventilation in subjects with neuromuscular diseases. Respir Care 2018;63:274–81.

[30] Carroll JE, Zwillich CW, Weil JV. Ventilatory response in myotonic dystrophy. Neurology 1977;27:1125–8.

[31] Begin R, Bureau MA, Lupien L, et al. Pathogenesis of respiratory insufficiency in myotonic dystrophy: the mechanical factors. Am Rev Respir Dis 1982;125:312–8.

[32] Begin P, Mathieu J, Almirall J, et al. Relationship between chronic hypercapnia and inspiratory-muscle weakness in myotonic dystrophy. Am J Respir Crit Care Med 1997;156:133–9.

[33] Serrier DE, Mastaglia FL, Gibson GJ. Respiratory muscle function and ventilatory control. I in patients with motor neurone disease. II in patients with myotonic dystrophy. Q J Med 1982;51:203–26.

[34] Ono S, Kanda F, Takahashi K, et al. Neuronal loss in the medullary reticular formation in myotonic dystrophy: a clinicopathological study. Neurology 1996;46:228–31.

[35] Ono S, Takahashi K, Jinmai K, et al. Loss of catecholaminergic neurons in the medullary reticular formation in myotonic dystrophy. Neurology 1998;51:1121–4.

[36] Ono S, Takahashi K, Kanda F, et al. Decrease of neurons in the medullary arcuate nucleus in myotonic dystrophy. Acta Neuropathol 2001;102:89–93.

[37] Benaim S, Worster-Drought C. Dystrophia myotonica with myotonia of the diaphragm causing pulmonary hypoventilation with anoxaemia and secondary polycythaemia. Med Illus 1954;8:221–6.

[38] Jammes Y, Pouget J, Grimaud C, et al. Pulmonary function and electromyographic study of respiratory muscles in myotonic dystrophy. Muscle Nerve 1985;8:586–94.

[39] Evangelista MA, Dias FAL, Dourado Junior MET, et al. Noninvasive assessment of respiratory muscle strength and activity in Myotonic dystrophy. PLoS One 2017;12:e0177318.

[40] Lavietes MH, Clifford E, Silverstein D, et al. Relationship of static respiratory muscle pressure and maximum voluntary ventilation in normal subjects. Respiration 1979;38:121–6.

[41] Bogaard JM, van der Meche FG, Hendriks I, et al. Pulmonary function and resting breathing pattern in myotonic dystrophy. Lung 1992;170:143–53.